Seminars in Oncology Nursing
Volume 25, Issue 1 , Pages 61-75 , February 2009

Tumors of the Esophagus, Gastroesophageal Junction, and Stomach

References 

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96
  2. American Cancer Society: Cancer statistics, 2008. Available at: http://www.cancer.org/docroot/STT/STT_0.asp (accessed on June 1, 2008).
  3. Blot WJ, McLaughlin JK. The changing epidemiology of esophaeal cancer. Semin Oncol. 1999;26(Suppl 15):2–8
  4. Kalish RJ, Clancy PE, Orringer MB, et al. Clinical, epidemiologic, and morphologic comparison between adenocarcinomas arising in Barrett’s esophaeal mucosa and the gastric cardia. Gastroenterology. 1984;86:461–467
  5. American Joint Commission on Staging. Cancer Staging. 6th ed. Chicago, IL: American Joint Commission on Staging; 2002. Available at: www.cancerstaging.org.
  6. Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adennocarcinoma incidence. J Natl Cancer Inst. 2005;97:142–146
  7. Pera M, Manterola C, Vidal O, et al. Epidemiology of esophageal adenocarcinoma. J Surg Oncol. 2005;92:151–159
  8. Layke JC, Lopez PP. Esophageal cancer: a review and update. Am Fam Phys. 2006;73:2187–2194
  9. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparity in different geographic regions of the world. J Clin Oncol. 2006;24:2137–2150
  10. Spechler SJ, Goyal RK. The columnar-lined esophagus, intestinal metaplasia, and Norman Barrett. Gastroenterology. 1996;110:614–621
  11. Cameron AJ, Lomboy CT, Pera M, et al. Adenocarcinoma of the esophagogastric junction and Barrett’s esophagus. Gastroenterology. 1995;109:1541–1546
  12. Wang KK, Sampliner RE. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett’s esophagus. Am J Gastroenterol. 2008;103:788–797
  13. Robertson EV, Jankowski JA. Genetics of gastroesophageal cancer: paradigms, paradoxes, and prognostic utility. Am J Gastroenterol. 2008;103:443–449
  14. Ruder AM, Ward EM, Brown DP. Cancer mortality in female and male dry-cleaning workers. J Occup Med. 1994;36:867–874
  15. Merry AH, Schouten LJ, Goldbohm RA, et al. Body mass index, height and risk of adenocarcinoma of the oesophagus and gastric cardia: a prospective cohort study. Gut. 2007;56:1503–1511
  16. Sandler RS, Nyren O, Ekbom A, et al. The risk of esophageal cancer in patients with achalasia. A population-based study. JAMA. 1995;274:1359–1362
  17. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349:2241–2252
  18. Far AE, Aghakhani A, Hamkar R, et al. Frequency of human papillomavirus infection in oesophageal squamous cell carcinoma in Iranian patients. Scand J Infect Dis. 2007;39:58–62
  19. Kountouras J, Zavos C, Chatzopoulos D, et al. New aspects of Helicobacter pylori infection involvement in gastric oncogenesis. J Surg Res. 2008;146:149–158
  20. Medina-Franco H, Barreto-Zuniga R, Garcia-Alvarez MN. Presumptive total gastrectomy for hereditary gastric cancer. J Gastrointest Surg. 2007;11:314–317
  21. Edmondson D, Schiech L. Esophageal cancer-a tough pill to swallow. Nursing. 2008;38:44–50
  22. Axon A. Symptoms and diagnosis of gastric cancer at early curable stage. Best Practice Res Clin Gastroenterol. 2006;20:697–708
  23. Weber WA, Ott K. Imaging of esophageal and gastric cancer. Semin Oncol. 2004;31:530–541
  24. National Comprehensive Cancer Network. www.nccn.org/professionals/physician_gls/PDF/esophageal.pdf (V.1.2009).
  25. National Comprehensive Cancer Network. www.nccn.org/professionals/physician_gls/PDF/esophageal.pdf (V.2.2009).
  26. Pfau PR, Perman SB, Stanko P, et al. The role and clinical value of EUS in a multimodality esophageal carcinoma staging program with CT and positon emission tomography. Gastrointest Endosc. 2007;65:377–384
  27. Ajani J, Bekaii-Saab T, D'Amico TA, et al. Esophageal cancer clinical practice guidelines. J Natl Compr Cancer Netw. 2006;4:328–347
  28. Ajani J, Bekaii-Saab T, D'Amico TA, et al. Gastric cancer clinical practice guidelines. J Natl Compr Cancer Netw. 2006;4:350–356
  29. Bruzzi JF, Swisher SG, Truong MT, et al. Detection of interval distant metastases: clinical utility of integrated CT-PET imaging in patients with esophageal carcinoma after neoadjuvant therapy. Cancer. 2007;109:125–134
  30. Wilson M, Rosato EL, Chojnacki KA, et al. Prognostic significance of lymph node metastases and ratio in esophageal cancer. J Surg Res. 2008;146:11–15
  31. Chau I, Norman AR, Cunningham D, et al. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer-pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol. 2004;22:2395–2403
  32. Hulscher JB, Tijssen JG, Obertop H, et al. Transthoracic versus transhiatal resection for carcinoma of the esophagus: a meta-analysis. Ann Thorac Surg. 2001;72:306–313
  33. Luketich JD, Alvelo-Rivera M, Buenaventura PO, et al. Minimally invasive esophagectomy: outcomes in 222 patients. Ann Surg. 2003;238:486–494
  34. Mackenzie DJ, Popplewell PK, Billingsly KG. Care of patients after esophagectomy. Crit Care Nurse. 2004;24:16–29
  35. Spechler SJ. Clinical practice Barrett’s esophagus. N Engl J Med. 2002;346:836–842
  36. Hulscher JBF, van Sandick JW, deBoer AGEM, et al. Extended transthoracic resection compared to limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med. 2002;347:1662–1669
  37. Birkmeyer JD, Siewers AE, Finlayson EV, et al. Hospital volume and surgical mortality in the United States. N Engl J Med. 2002;347:1128–1137
  38. Galvani Ca, Gorodne MV, Moser F, et al. Robotically assisted laparoscopic transhiatal esophagectomy. Surg Endosc. 2008;22:188–195
  39. Lambert R. Upper gastrointestinal tumors. Endoscopy. 2008;40:131–135
  40. DeMeester SR. New options for the therapy of Barrett’s high-grade dysplasia and intramucosal adenocarcinoma: endoscopic mucosal resection and ablation versus vagal-sparing esophagectomy. Ann Thorac Surg. 2008;85:S747–S750
  41. Graham AJ, Shrive FM, Ghali WA, et al. Defining the optimal treatment of locally advanced esophageal cancer: a systematic review and decision analysis. Ann Thorac Surg. 2007;83:1257–1264
  42. Herskovic A, Martz K, al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992;326:1593–1598
  43. al-Sarraf M, Martz K, Herskovic A, et al. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J Clin Oncol. 1997;15:277–284
  44. Kelsen DP, Ginsberg R, Pajak TF, et al. Chemotherapy followed by surgery compared with surgery compared with surgery alone for localized esophageal cancer. N Engl J Med. 1998;339:1979–1984
  45. Kelsen DP, Winter KA, Gunderson LL, et al. Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparision of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol. 2007;25:3719–3725
  46. Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy and surgery compared with surgery alone for esophageal cancer. CALGB 9781. J Clin Oncol. 2007;26:1086–1092
  47. Macdonald JS, Smalley SR, Beneditti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725–730
  48. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20
  49. Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810–1820
  50. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus flourouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol. 2006;24:4991–4997
  51. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358:36–46
  52. Ilson DH, Saltz L, Enzinger P, et al. Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol. 1999;17:3270–3275
  53. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–2342
  54. Shah MA, Ramanathan RK, Ilson DH, et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol. 2006;24:5201–5206
  55. Dragovich T, McCoy S, Fenoglio-Preiser CM, et al. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol. 2006;24:4922–2937
  56. Ferry DR, Anderson M, Beddard K, et al. A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response. Clin Cancer Res. 2007;13:5869–5875
  57. Boeing H, Dietrich T, Toffman K, et al. Intake of fruits and vegetables and risk of cancer of the upper aero-digestive tract: the prospective EPIC-study. Cancer Causes Control. 2006;17:957–969
  58. Conley DA, Kerlikowske K, Verma R, et al. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology. 2003;124:47–56
  59. Hasler WL. Dumping syndrome. Curr Treat Options Gastroenterol. 2002;5:139–145
  60. Dietitian's patient education manual. 2nd ed. Gaithersburg, MD: Center for Patient Education; 2001;
  61. Shils ME, Olsen JA, Shike M. Modern nutrition in health and disease. 9th ed. Philadelphia, PA: Lippincott Williams & Williams; 1999;
  62. American Dietetic Association. Nutrition Care Manual. Available at: www.eatright.org/cps/rde/xchg/ada/hs.xsl. (accessed Feb 12, 2008).
  63. Gabor S, Renner H, Matzi V, et al. Early enteral feeding compared with parenteral nutrition after oesphageal or oesophagogastric resection and reconstruction. Br J Nutr. 2005;93:509–513
  64. Takeuchi H, Ikeuchi S, Kasaguchi Y, et al. Clinical significance of perioperative immunonutrition for patients with esophageal cancer. World J Surg. 2007;31:2160–2167
  65. Adachi S, Kawamoto T, Otsuka M, et al. Enteral vitamin B12 supplements reverse postgastrectomy B12 deficiency. Ann Surg. 2000;23:199–201
  66. Sweed MR, Schiech L, Barsevick A, et al. Quality of life after esophagectomy for cancer. Oncol Nurs Forum. 2002;29:1127–1131

PII: S0749-2081(08)00076-4

doi: 10.1016/j.soncn.2008.10.005

Seminars in Oncology Nursing
Volume 25, Issue 1 , Pages 61-75 , February 2009

Article Tools

* Image Usage & Resolution